<SEC-DOCUMENT>0001628280-23-020480.txt : 20230601
<SEC-HEADER>0001628280-23-020480.hdr.sgml : 20230601
<ACCEPTANCE-DATETIME>20230601145047
ACCESSION NUMBER:		0001628280-23-020480
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230531
FILED AS OF DATE:		20230601
DATE AS OF CHANGE:		20230601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		23984289

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybin-lpcxmcr6xk.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i596f8b514958421d8988bc5fc73d8b87_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the month of June, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Form 40-F </font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:10pt;font-weight:400;line-height:100%">&#8864;</font></div><div><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INCORPORATION BY REFERENCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1 of this Form 6-K of Cybin Inc. (the &#8220;Company&#8221;) are hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-259994) of the Company, as amended or supplemented.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="cybn-materialchangereportj.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">M</a><a href="cybn-materialchangereportj.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">aterial Change </a><a href="cybn-materialchangereportj.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">R</a><a href="cybn-materialchangereportj.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">eport Dated</a><a href="cybn-materialchangereportj.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="cybn-materialchangereportj.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">May 3</a><a href="cybn-materialchangereportj.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a><a href="cybn-materialchangereportj.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">, 2023</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cybn-materialchangereportj.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1e0401c563334079afbc06422eced0e7_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:40.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FORM 51-102F3</font></div><div style="margin-bottom:6pt;text-align:center;text-indent:40.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MATERIAL CHANGE REPORT</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 1. Name and Address of Company</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cybin Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100 King Street West, Suite 5600</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Toronto, Ontario</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">M5X 1C9</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 2. Date of Material Change</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">May 30, 2023</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 3. News Release</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A news release with respect to the material change was disseminated by the Company on May 30, 2023 through BusinessWire (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">News Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 4. Summary of Material Change</font></div><div style="margin-top:0.05pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">On May 30, 2023, the Company announced that it had entered into a purchase agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), an institutional investor. The Purchase Agreement allows the Company to issue and sell up to US$30,000,000 of common shares in the capital of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) over a 36-month period at prices that are based on the market price at the time of each sale to LPC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). As consideration for LPC&#8217;s obligation to purchase Shares from the Company at the Company&#8217;s discretion under the Purchase Agreement, the Company issued 2,538,844 Shares to LPC as a commitment fee. </font></div><div style="margin-top:0.05pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Offering is made pursuant to and qualified by way of a prospectus supplement dated May 30, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the Company&#8217;s short form base shelf prospectus dated July 5, 2021 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Base Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Supplement was filed with the Ontario Securities Commission and with the United States Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as part of a registration statement on Form F-10, which was declared effective by the SEC on October 8, 2021, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. No offers or sales of any Shares will be made in Canada or on the NEO Exchange Inc. pursuant to the Purchase Agreement or the Supplement and accompanying Base Prospectus.</font></div><div style="margin-top:0.05pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Purchase Agreement provides that the Company may not issue or sell any Shares to LPC under the Purchase Agreement which, when aggregated with all other Shares then beneficially owned by LPC and its affiliates (as calculated pursuant to Section 13(d) of the U.S. Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in LPC beneficially owning more than 9.99% of the outstanding Shares. </font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 5. Full Description of Material Change</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">See the full text of the News Release attached hereto as Schedule &#8220;A&#8221;. </font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Not applicable.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 7. Omitted Information</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Not applicable.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 8. Executive Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Further information regarding the matters described in this report may be obtained from Gabriel Fahel, Chief Legal Officer of the Company, who is knowledgeable about the details of the material change and may be contacted at 1-866-292-4601.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 9. Date of Report</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">May 31, 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1e0401c563334079afbc06422eced0e7_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule &#8220;A&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:143px;margin-bottom:5pt;vertical-align:text-bottom;width:247px"></div><div style="padding-left:5.77pt;padding-right:5.77pt;text-align:center;text-indent:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Cybin Announces US$30M Common Stock Purchase Agreement </font></div><div style="padding-left:5.77pt;padding-right:5.77pt;text-align:center;text-indent:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">from Lincoln Park Capital Fund</font></div><div style="padding-left:5.77pt;padding-right:5.77pt;text-align:center;text-indent:0.25pt"><font><br></font></div><div style="margin-top:12.6pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:123%"> - Share purchase agreement further strengthens Company&#8217;s position to deliver on value-driving clinical milestones -</font></div><div style="margin-top:12.6pt;padding-right:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:123%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">&#8211; May 30, 2023 &#8211; Cybin Inc. (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%;text-decoration:underline">NEO&#58;CYBN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">) (NYSE American&#58; CYBN) (&#8220;Cybin&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has entered into a common share purchase agreement (the &#8220;Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;), an institutional investor.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">Subject to the terms and conditions of the Agreement, Cybin has the right to sell, and LPC is obligated to purchase, up to US$30 million (CAD$41 million)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:123%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">of the Company&#8217;s common shares over a 36-month period at prices that are based on the market price at the time of each sale to LPC. Cybin, in its sole discretion, controls the timing and amount of all sales of common shares under the Agreement, and there are no warrants, derivatives, or other share classes associated with this Agreement. </font></div><div style="margin-top:12.6pt;padding-right:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">&#8220;This committed equity facility by LPC provides us with access to capital on an as-needed basis and is expected to allow Cybin to best utilize market conditions to raise capital in support of our drug development programs,&#8221; said Doug Drysdale, Chief Executive Officer of Cybin. &#8220;The ability to further strengthen our cash position through sales of common shares to LPC under this facility provides additional runway for our success moving forward.&#8221;</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">Cybin has the right to terminate the Agreement at any time at no cost or penalty. LPC has agreed not to engage in any short selling or hedging activity of any kind in the Company&#8217;s common shares. As consideration for LPC&#8217;s obligation to purchase common shares from Cybin at our direction under this Agreement, Cybin has issued 2,538,844 common shares to LPC as a commitment fee. </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">The sale of common shares under the Agreement will be made pursuant to and qualified by way of a prospectus supplement, dated May 30, 2023 (the &#8220;Supplement&#8221;), to the Company&#8217;s short form base shelf prospectus dated July 5, 2021 (the &#8220;Base Prospectus&#8221;) filed with the securities </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">commissions in each of the provinces and territories of Canada. The Supplement was also filed with the United States Securities and Exchange Commission (the &#8220;SEC&#8221;), as part of a registration statement on Form F-10, which was declared effective by the SEC on October 8, 2021, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. No offers or sales of any common shares will be made in Canada or on the NEO Exchange pursuant to the Agreement or the Supplement and accompanying Base Prospectus.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">The Supplement and accompanying Base Prospectus contain important detailed information about the Agreement. The Agreement, the Supplement and accompanying Base Prospectus can be found under the Company&#8217;s profile on SEDAR at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%;text-decoration:underline">www.sedar.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%"> and with the SEC on EDGAR at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:123%">.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:123%">This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Cybin</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. </font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on Twitter, LinkedIn, You Tube and Instagram. </font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin&#8217;s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;aim&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;would&#8221;, &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;forecast&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;seek&#8221;, &#8220;should&#8221; or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the potential sale of common shares under the Agreement and the Company&#8217;s ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">implications of the COVID-19 pandemic on the Company&#8217;s operations&#59; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; and the risk factors set out in the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2022, the Company&#8217;s annual information form for the year ended March 31, 2022, and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on www.sedar.com and with the SEC on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investor &#38; Media Contact</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gabriel Fahel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Legal Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cybin Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1-866-292-4601</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">irteam&#64;cybin.com &#8211; or &#8211; media&#64;cybin.com</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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M@6*$.!DX)[%G#II4'JG8W7<@V*.P4YN-9^Y3RF!P=WGJT4^)%?=YLY(F5>+
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M>;DL\Q6I&$\.SA*XD$8Q0CTKU.,P,+BV>'UV]/)OSH#HS4<G,4'\?W$"/SD
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MQX ]:.-,<'.E>!3M1Q1W(A]%150Z=R\<$TSI:=&'9P&F<NR7,6:;ZY1A3J:
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M,1T^";N/O+M@8(,5"AIX+N2 O7B=3U?+UX/-CN2@?)'/^O>3CO7SA!>OCG(
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ML00"V6];?'K$Q?W(^',@P,G'_GU,**(@!4TJ5&E I-G'2 &TQVS03J.0+.$
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M-2@IW20**?V@[ @.4)= VR*)OH.*BNE5/7<_D_$G0)J37YA^4;11*=;J0I!
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M\^> :2JPNEBKRM=.,H8%F9,'@)NS([$&.G9T>ZQP:2?+%WGN,!DR!@>9DP>
M>J7LT:D$+Y-]!B6MGRJD@MPQ,F0,%#(G#P+M=B[DB*_-=89JVIDR]![M5/$H
MQOV\#!F#ALS)@T'CJ99TK(8M,V PNU;&7$SQZJ!UX5J^<Y+Q+I Y>6!H-AJ%
K9#"\K::-,Q[C;(;:J):ON1^2(6,X^'\FP^6FWC4CM     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
